IDiyas

For the Inventor, By the Inventor

Tokyo, Japan

Kiyoshi Hamano

USPTO Granted Patents = 8

Average Co-Inventor Count = 6.0

ph-index = 5

Forward Citations = 56(Granted Patents)


Location History:

  • Hiromachi, JP (1982 - 1993)
  • Tokyo, JP (1992 - 1998)

Company Filing History:

goldMedal8 out of 613 
 
Sankyo Company, Limited
 patents

Years Active: 1982-1998

Loading Chart...
8 patents (USPTO):Explore Patents
1. 5827855 - Hexahydronaphthalene ester derivatives their preparation and their (1998-10-27),
2. 5451688 - Hexahydronaphthalene ester derivatives, their preparation and their (1995-09-19),
3. 5272174 - Hydroxy-ML-236B derivatives, their preparation and use (1993-12-21),
4. 5260447 - Polyhydroxycyclopentane derivatives, their preparation and their (1993-11-09),
5. 5153124 - Hydroxyl-ML-236B derivatives, their preparation and use (1992-10-06),
6. 5112807 - Compound 'Leualacin', its preparation and its use in the treatment of (1992-05-12),
7. 4438277 - Hydronaphthalene derivatives (1984-03-20),
8. 4361515 - Antihyperlipemic dihydro-ML-236B derivatives, their preparation and use (1982-11-30),

Title: Kiyoshi Hamano: Innovator in Cholesterol Inhibition

Introduction

Kiyoshi Hamano is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit cholesterol synthesis. With a total of 8 patents to his name, Hamano's work has the potential to impact the treatment of various cardiac disorders.

Latest Patents

Hamano's latest patents focus on hexahydronaphthalene ester derivatives. These compounds are designed to inhibit the synthesis of cholesterol, making them valuable for the treatment and prophylaxis of hypercholesterolemia and various cardiac disorders. The compounds are characterized by specific formulas that include various alkyl, alkenyl, and alkynyl groups, as well as carboxy-protecting groups. The innovative nature of these compounds lies in their ability to provide therapeutic benefits while minimizing side effects.

Career Highlights

Kiyoshi Hamano is currently associated with Sankyo Company, Limited, where he continues to advance his research and development efforts. His work has garnered attention in the pharmaceutical industry, particularly for its implications in cardiovascular health.

Collaborations

Throughout his career, Hamano has collaborated with notable colleagues such as Yoshio Tsujita and Kouhei Furuya. These partnerships have contributed to the successful development of his innovative compounds.

Conclusion

Kiyoshi Hamano's contributions to the field of cholesterol inhibition through his patented compounds highlight his role as a leading inventor in the pharmaceutical industry. His work not only addresses critical health issues but also showcases the importance of innovation in medical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…